Antibody Mediated Rejection Associated With Complement Factor H–Related Protein 3/1 Deficiency Successfully Treated With Eculizumab

This publication has 33 references indexed in Scilit:

• Treatment options and strategies for antibody mediated rejection after renal transplantation
  Seminars in Immunology, 2012
• Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab
  European Journal of Haematology, 2011
• Inhibiting the C5–C5a receptor axis
  Molecular Immunology, 2011
• Thrombotic Microangiopathy and Peritubular Capillary C4d Expression in Renal Allograft Biopsies
  Clinical Journal of the American Society of Nephrology, 2011
• Antibody-mediated rejection in kidney transplantation: an update
  Expert Opinion on Pharmacotherapy, 2011
• Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies
  Best Practice & Research Clinical Haematology, 2009
• The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantation
  Nephrology Dialysis Transplantation, 2009
• Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
  Clinical Journal of the American Society of Nephrology, 2009
• The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody-Mediated Rejection
  American Journal of Transplantation, 2009
• Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
  American Journal of Transplantation, 2003